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ABSTRACT 
 
Gastric emptying is a complex process and makes the in vivo performance of the drug delivery system uncertain. In 
order to avoid this fickleness, efforts have been made to increase the retention time of the dosage form, that is the 
development to gastroretentive drug delivery system. Gastroretentive drug delivery system (GRDDS) can remain in 
the stomach for prolonged period of time and there by increases gastric residence time of drugs, and also improves 
the bioavailability of certain drugs. These are widely used for the site specific drug delivery, for the treatment of 
gastrointestinal diseases and disorders. There are several approaches of Gastroretentive drug delivery system which 
are discussed in detail in the present review. Recent patents on (GRDDS) are also enlisted with a detailed 
description of evaluation parameters of the same. 
 
Key words: Approaches of GRDDS, Evaluation parameters, Gastro-retentive drug delivery system, probable 
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Introduction 
 
The high level of patient compliance in taking oral 
dosage forms is due to the ease of administration and 
handling of these forms. Although tremendous 
advances have been seen in oral controlled drug 
delivery system in the last two decades, this system has 
been of limited success in the case of drugs with a poor 
absorption window throughout the GIT (Gastro 
Intestinal Tract). In the development of oral controlled 
drug delivery system, one of the main challenges is to 
modify the GI transit time. Gastric emptying of 
pharmaceuticals is highly variable, which could be 
illustrated below in a tabular form and is dependent on 
the dosage form and the fed/fasted state of the stomach. 
Normal gastric residence time usually ranges between 
5 minutes and 2 hours. In the fasted state the electrical 
activity in the stomach – the interdigestive myoelectric 
cycle or migrating myoelectric complex (MMC)  
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governs the activity and, hence, the transit of dosage 
forms. It is characterized by four phases: 
Phase I–Period of no contraction (40-60 minutes), 
phase II –Period of intermittent contractions (20-40 
minutes), phase III–Period of regular contractions at 
the maximal frequency that travel distally also known 
as housekeeper wave. (10-20 minutes) and phase IV–
Period of transition between phase III and phase I (0-5 
minutes) [1]. 
If there are physiological problems and other factors 
like the presence of food then gastric emptying is 
unpredictable. Drugs having a short half-life are 
eliminated quickly from the blood circulation. Various 
oral controlled delivery systems have been designed 
which can overcome these problems and release the 
drug to maintain its plasma concentration for a longer 
period of time.This has led to the development of oral 
Gastroretentive dosage forms. Gastroretention is 
essential for drugs that are absorbed from the stomach, 
drugs that are poorly soluble or degraded by the higher 
pH of intestine, and drugs with an absorption which 
can be modified by changes in gastric emptying time. 
Gastroretentive dosage forms are also useful for local 
as well as sustained drug delivery for certain 
conditions, like H. pylori infection which is the cause 
of peptic ulcers. This dosage form improves 
bioavailability, therapeutic efficacy and may even also 
allow a possible reduction in the dose because of 
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steady therapeutic levels of drug, for example 
furosemide and ofloxacin. The reduction in fluctuations 
in therapeutic levels minimizes the risk of resistance 
especially in case of β-lactam antibiotics (penicillins 
and cephalosporins) [2] 
 
 
Table 1: Advantages and disadvantages of FDDS [3] 
 
Advantages Disadvantages 
1. Improved drug absorption 1. GRDDS is not suitable for drugs with stability or 
solubility problems in the stomach. 
2. Controlled drug delivery 2. It requires sufficiently high level of fluid in the 
stomach so that the system floats and thus sufficient 
amount of water (200–250 ml) to be taken together 
with the dosage form. 
3. Minimizing the mucosal irritation 3. Drugs having irritant effect on gastric mucosa are not 
suitable for GRDDS. 
4. Delivery of drug for local action in the stomach 4. Drugs which are absorbed along the entire GIT and 
which undergoes first pass metabolism may not be 
desirable e.g. nifedipine. 
5. Treatment of gastrointestinal diseases.  
6. Simple and conventional equipment for 
manufacturing process. 
 
7. Site-specific drug delivery.  
8. Ease of administration and better patient compliance  
 
Table 2: Anatomical and physiological features of GIT [4] 
 
Section 
 
Average 
length(cm) 
Diameter(
cm) 
Absorption 
mechanism 
pH 
 
Major constituents 
 
Transit time(h) 
Oral cavity 
 
15-20 10 Passive diffusion 5.2-6.8 Amylase, maltase, 
mucin 
 
Short 
 
Stomach 
 
20 15 Passive diffusion 
 
1.2-3.5 
 
Hydrochloric acid, 
pepsin, rennin, lipase, 
intrinsic factor 
0.25-3.0 
 
Duodenum 
 
25 5 Passive diffusion, 
active transport, 
facilitated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
tra   ir, pinocy-tosis 
4.6-6.0 
 
Bile, trypsin, chymo- 
trypsin, amylase, 
maltase, lipase, 
nuclease, CYP3A5 
1-2 
 
Jejunum 
 
300 
 
5 Passive diffusion, 
active transport, 
facilitated transport 
6.3-7.3 
 
Amylase, maltase, 
lactase, sucrase, 
CYP3A5 
 
- 
Ileum 
 
300 
 
2.5-5.0 
 
Passive diffusion, 
active transport, 
facilitated transport, 
ion pair,pinocytosis 
                                                       
 
Lipase, nuclease, 
nucleotidase, 
 
1-10 
 
Cecum 
 
10-30 
 
7 
 
Passive diffusion, 
active transport, pino- 
cytosis 
7.5-8.0 
 
- 
 
Short 
 
Colon 150 5 
 
Passive diffusion 7.9-8 - 4-20 
Rectum 
 
15-19 
 
2.5 
 
Passive diffusion, 
pinocytosis 
7.5-8.0 - Variable 
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Factors affecting gastric retention time of the 
dosage form[5]  
1. Density 
2.  Size & Shape of formulation 
3. Single or multiple unit formulation 
4. Fed or unfed state 
5. Nature of meal 
6. Caloric content 
7. Frequency of feed 
8. Gender 
9. Age 
10. Posture 
11. Concomitant drug administration 
12. Disease state 
 
Approaches to achieve gastric retention 
 
Different approaches have been pursued to increase the 
retention of oral dosage forms in the stomach. Some 
are formulated as single component whereas others are 
formulated as multi-component dosage forms. GRDDS 
can be broadly categorized into floating and non-
floating system. 
 
A. Non-floating system 
Non-floating system is further divided into:  
1. High density (sinking) drug delivery system  
2. Bioadhsive or mucoadhesive system  
3. Magnetic system  
4. Swelling/ Expanding Systems  
B. Floating drug delivery systems (FDDS) 
Floating drug delivery system can be divided into:  
1. Effervescent system 
1.1) Volatile liquid containing systems  
a) Intragastric floating gastrointestinal drug delivery 
b) Inflatable gastrointestinal drug delivery system 
c) Intragastricosmotically controlled drug delivery 
system 
1.2) Gas generating systems 
a) Floating capsules 
b) Floating pills 
C) Floating systems with ion exchange resins 
2. Non effervescent system  
2.1Hydrodynamically balanced system  
2.2 Microbaloons or hollow microspheres  
2.3 Alginate beads  
2.4 Microporous compartment  
2.5Raft systems 
2.6Superporous hydrogel 
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Fig 1: Showing the high density systems which are at the bottom of the stomach and low density systems 
which are floating 
 
 
A. Non-floating system  
1. High Density (Sinking) Drug Delivery System  
Here dosage formis prepared by coating drug on a 
heavy core or mixed with inert materials such as iron 
powder, barium sulfate, zinc oxide and titanium oxide 
so that the density of the formulation exceeds the 
density of the normal gastric content [6].They increase 
the density up to 1.5-2.4 gm/cm
3
. But effectiveness of 
this system in human beings was not observed [7]and 
no formulation has been marketed.  
Fig.1Showing the high density systems which are at 
the bottom of the stomach and low density systems 
which are floating 
2. Bioadhesive or mucoadhesive system  
These systems bind to the gastric epithelial cell surface, 
or mucin, and increase the GRT by increasing the 
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duration of contact between the dosage form and the 
biological membrane. A bio mucoadhesive substance is 
a natural or synthetic polymer capable of adhering to a 
biological membrane (bio-adhesive polymer) or the 
mucus lining of the GIT (mucoadhesive polymer). The 
characteristics of these polymers are 
 Molecular flexibility, hydrophilic functional groups, 
chain length, and conformation 
Furthermore, they must be  
 Nontoxic and non-absorbable 
  Form noncovalent bonds with the mucin–
epithelial surfaces 
 Have quick adherence to moist surfaces 
 Easily incorporate the drug and offer no hindrance 
to drug release 
 Have a specific site of attachment, and be 
economical.  
 
Fig.2 Bioadhesive drug delivery system 
3. Magnetic systems 
Here the dosage form contains a small internal magnet 
and a magnet placed on the abdomen over the position 
of the stomach. Ito et al. used this technique in rabbits 
with bioadhesive granules containing ultrafine ferrite 
(g-Fe2O3). They guided them to the oesophagus with an 
external magnet (1700 G) for the initial 2 min and 
almost all the granules were retained in the region after 
2 hr [8]. 
 
 
Fig 3:Magnetic systems 
4. Swelling/ Expanding Systems 
After being swallowed, these dosage forms swell to a 
size that prevents their passage through the pylorus. As 
a result, the dosage form is retained in the stomach for 
a long period of time. These systems are sometimes 
referred to as plug type systems because they tend to 
remain lodged at the pyloric sphincter. These 
polymeric matrices remain in the gastric cavity for 
several hours even in the fed state. Sustained and 
controlled drug release may be achieved by selecting a 
polymer with the proper molecular weight and swelling 
properties.   
Expandable System 
The extensive swelling of these polymers is due of the 
presence of physical-chemical crosslinking in the 
hydrophilic polymer network. These cross-links 
prevent the dissolution of the polymer and thus 
maintains the physical integrity of the dosage form. A 
balance between the extent and duration of swelling is 
maintained by the degree of cross linking between the 
polymeric chains. A high degree of crosslinking retards 
the swelling ability of the system and maintains its 
physical integrity for a prolonged period. On the other 
hand, a low degree of cross-linking results in extensive 
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swelling followed by the rapid dissolution of the 
polymer. 
An optimum amount of cross-linking is required to 
maintain a balance between swelling and dissolution. 
The swollen system eventually will lose its integrity 
because of a loss of mechanical strength caused by 
abrasion or erosion or will burst into smaller fragments 
when the membrane ruptures because of continuous 
expansion. [9] 
The expandable GRDFs are usually based on three 
configurations: 
 A small collapsed configuration which enables 
sufficient oral intake 
 Expanded form that is achieved in the stomach 
after swelling and thus prevents passage through 
the pyloric sphincter. 
 A smaller form that is achieved in the stomach 
when the retention is no longer required i.e. after 
the GRDF has released its active ingredient, 
thereby enabling evacuation. 
The expansion can be achieved by 
i) Swelling system   ii) Unfolding system 
 
 
Fig 4: Swellable system 
 
 
Fig 5: Various geometric forms of unfolding system 
 
 
B. Floating Drug Delivery System  
1. Effervescent system 
These dosage forms are developed insuch a way that, 
when they come incontact with gastric juices in the 
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stomach, carbon dioxide gas is released due to the 
reaction between sodium bicarbonate, citric acid and 
tartaric acid and is trapped in the swollen 
hydrocolloids. This provides buoyancy to the dosage 
form thereby making it to float on the gastric fluid. 
These systems may alsocontain liquids which gasify 
and evaporates at body temperature bywhich the 
specific gravity decreases and causes the dosage form 
to float. These effervescent systems have been further 
classified into different types: 
1.1) Volatile liquid containing systems[10] 
These are further classified as 
a) Intragastric floating gastrointestinal drug 
delivery systems: These systems are made tofloat in 
the stomach because of the floating chamber, which 
may be filled with air or vaccum or harmless gas, and 
the drug reservoir is encapsulated inside a micro 
porous compartment. This micro porous compartment 
has pores on the top and bottom surfaces, whereas the 
peripheral walls of the reservoir compartment were 
completely sealed to prevent any physical contact of 
the undissolved drug with the walls of the stomach. 
b) Inflatable gastrointestinal drug delivery system: 
These systems consist of inflatable chamber with liquid 
ether that gasifies at body temperature making the 
chamber toinflate in the stomach. This inflatable 
chamber contains a drug reservoir which is 
encapsulated in a gelatin capsule. After oral 
administration, the capsule dissolves and releases the 
drug reservoir together with the inflatable. 
 
Fig  6 : Gastro inflatable drug delivery device 
c) Intragastric osmotically controlled drug delivery system: It consists of osmotic pressure controlled drug 
delivery device and an inflatable support in a biodegradable capsule. On reaching the stomach, inflatable capsule 
disintegrates and releases the osmotically controlled drug delivery.  
 
Fig 7: Intragastric osmotically controlled drug delivery system 
1.2. Gas generating systems [11] 
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In these systems floatability is achieved by generation of gas bubbles. Carbon dioxide is generated in situ by 
incorporation of carbonates or bicarbonates, which react with acid, either the natural gastric acid or co-formulated as 
citric or tartaric acid. The gas generated makes the system to float on the gastric fluid and releases the drug ata 
predetermined rate. These are of different types 
a. Floating capsules 
b.Floating pills 
C. Floating systems with ion exchange resins 
These systems are formulated by using ion exchange resins that are loaded with bicarbonate by mixing the beads 
with sodium bicarbonate solution. 
 
 
Fig 8: Floating system with ion exchange resins 
 
 
2) Non effervescent systems 
Non effervescent systems incorporate a high level (20–75% w/w) of one or more gel-forming, highly swellable, 
cellulosic hydrocolloids .Upon coming into contact with gastric fluid, these gel formers, polysaccharides, and 
polymers hydrate and forms a colloidal gel barrier that controls the rate of fluid penetration into the device and 
consequent drug release. 
2.1) Hydrodynamically balanced system: The hydrodynamically balanced system (HBS) was first designed by 
[12]. They are meant to remain buoyant on the stomach content. This system contains one or more gel forming 
cellulose type hydrocolloid e.g., hydroxypropyl methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, agar, 
carrageen or alginic acid. It also contains matrix forming polymers such as polycarbophil, polyacrylate and 
polystyrene. When such system comes in contact with gastric fluid, the hydrocolloid in the system hydrates and 
forms a colloid gel barrier around its surface. 
 
Fig 9:Hydrodynamically balanced system (HBS) 
  
2.2 Microballoons / Hollow microspheres: 
 
Asian Pac. J. Health Sci., 2016; 3 (4):131-144                                        e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ___________________________________________________________________________________________________________________________________________ 
Fatema et al             ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(4): 131-144 
www.apjhs.com      139 
 
Microballoons / hollow microspheres loaded with 
drugs in their outer polymeric shell were prepared by 
simple solvent evaporation or solvent diffusion / 
evaporation methods to prolong the gastric retention 
time (GRT) of the dosage form. 
Commonly used polymers to develop these systems are 
polycarbonate, cellulose acetate, calcium alginate, 
Eudragit S, agar and low methoxylated pectin etc. 
Buoyancy and drug release from dosage forms are 
dependent on  
 Quantity of polymers 
  The plasticizer polymer ratio and  
 The solvent used for formulation.  
At present hollow microspheres are considered to be 
one of the most promising buoyant systems because 
they combine the advantages of multiple-unit system 
and good floating. 
2.3 Alginate beads: Freeze dried calcium alginates 
have been used to develop multiunit floating dosage 
forms .By dropping sodium alginate solution into 
aqueous solution of calcium chloride ,spherical beads 
of about 2.5 mm diameter can be prepared. These 
beads are separated and air dried. This results in the 
formation of aporous system which remains buoyant in 
the stomach. 
2.4Microporous compartment: In this system, drug 
reservoir is encapsulated inside a microporous 
compartment having pores along its top and bottom 
walls. The floatation chamber containing entrapped air 
causes the delivery system to float over the gastric 
content. Gastric fluid enters through the aperture, 
dissolves the drug and releases it for absorption. 
 
Fig 10: Floating drug delivery device with microporous membrane and floatation chamber 
2.5 Raft systems 
This incorporates alginate gel and a carbonate 
component and, upon reaction with gastric acid, 
bubbles form in the gel, enabling floating. Raft forming 
systems produce a layer on the top of gastric fluid. 
Here, a gel forming solution (e.g. sodium alginate 
solution containing carbonates or bicarbonates)swells 
and forms a viscous cohesive gel containing entrapped 
CO2 bubbles on contact with gastric fluid. 
A patent assigned to Reckitt and Colman Products Ltd., 
describes a raft forming formulation for the treatment 
of Helicobacterpylori (H. Pylori) infections in the GIT 
[13]. The composition contained drug, alginic acid, 
sodium bicarbonate, calcium carbonate, mannitol and a 
sweetener. These ingredients were granulated, and 
citric acid was added to the granules. The formulation 
produces effervescence and aerates the raft formed, 
making it to float. 
 
Fig 11:Schematic illustration of the barrier formed by a raft-forming system 
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2.6 Superporous  hydrogels 
These are swellable systems that differ from 
conventional types. Absorption of water by 
conventional hydrogel is very slow process and several 
hours may be required to reach the equilibrium states 
[14] during which the premature evacuation of the 
dosage form may occur. Superporous hydrogel have a 
pore size >100μm which swell to equilibrium size 
within a minute, due to rapid intake of water by 
capillary wetting through inter connected open pores. 
They swell to a larger size and have sufficient 
mechanical strength to withstand the pressure by 
gastric contraction. This is achieved by coformulation 
of a hydrophilic particulate material, Ac-Di-Sol[15].   
 
1.3 PATENTS ON GRDDS 
 
Table 3: List of some patented gastro retentive drug delivery systems 
 
US patent No. Patent title Pub. Date 
US6710126 B1 Hydrogel composites and superporous hydrogel composites having fast swelling, 
high mechanical strength, and superabsorbent properties 
Aug. 7, 2001 
US 6,488,962 B1 Tablet shapes to enhance gastric retention of swellable controlled release oral 
dosage Forms 
Dec. 3, 2002 
WO 2002102415 A1 Gastric floating system 27 Dec 2002 
US 2008/0220060 A1 Gastroretentive formulations and   manufacturing process there of Sep. 1 1, 2008 
WO 2011048494 A2 Novel gastroretentive dosage forms of poorly soluble drugs  Apr 1, 2010 
WO 2011151708 A1 Gastroretentive dosage forms of gaba analogs 8 Dec 2011 
US 8808669 B2 Gastroretentive, extended release composition of therapeutic agent 19 Aug 2014 
 
Evaluation[16] 
 
 
(A) In vitro evaluation 
 
(i)Floating systems 
(a) Buoyancy lag time:  It is the time taken up by the dosage form to float on the top of the dissolution medium 
after being placed in the medium.  
(b) Floating time: Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid maintained at 37
0
 C.The 
time for which the dosage form continuously floats on the dissolution media istermed as floating time. 
(c) Resultant weight: Now, we know that bulk density and floating time are the main parameters for describing 
buoyancy. But only single determination of density is not sufficient to describe the buoyancy because density 
changes with change in resultant weight as a function of time. For example a matrix tabletwith bicarbonate and 
matrixing polymer floats initially by gas generation and entrapment but after sometime, some drug is released and 
simultaneously some outer part of matrixing polymer may erode out leading to change in resultant weight of 
dosageform.The magnitude and direction of force/resultant weight (up or down) is corresponding to its buoyancy 
force (Fbuoy) and gravity force (Fgrav) acting on dosage form (Fig. 14). 
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Fig 12 : Floating time and Resultant weight 
F = Fbuoy–Fgrav, F = Df g V – Ds g V, F = (Df– Ds) g V, F = (Df– M/V) g V 
Where, 
F = Resultant weight of object 
Df = Density of fluid 
Ds = Density of solid object 
g = Gravitational force 
M = Mass of dosage form 
V = Volume of dosage form 
So when Ds, density of dosage form is lower, F force is positive gives buoyancy and when it is Ds ishigher, F will 
be negative shows sinking. 
Plot of F vs. Time is drawn and floating time is time when F approaches to zero from positive values. 
(ii) Swelling systems 
(a) Swelling Index: After immersion of swelling 
dosage form into SGF at 37 
0
C, dosage form isremoved 
out at a regular intervals of time and dimensional 
changes are measured in terms of increase in 
tabletthickness/diameter with time. 
(b) Water Uptake [17]: It is an indirect measurement 
of swelling property of swellable matrix. Here dosage 
form is removed out at a regular intervals of time and 
weight changes are determined with respect to time. So 
it is also termed as Weight Gain. 
Water uptake = WU = (Wt – Wo) * 100 / Wo 
Where, Wt = Weight of dosage form at time t 
Wo = Initial weight of dosage form 
In this assembly concentric circles with various 
diameters are drawn in computer and print out 
islaminated to make hydrophobic. This laminated piece 
is attached with some system which can facilitate up 
and down movement of assembly. 
This assembly is placed in beaker and tablet is placed 
exactly at center and then there is no disturbance given 
to tablet. 
Tablet is allowed to swell on laminated paper and 
diameter can be easily noted without removing of a 
tablet. 
To determine water uptake/weight gain, whole 
assembly can bring out. Weighing of assembly done 
after wiping off water droplets adhered at surface of 
assembly and then can be placed back as it is without 
touching to tablet. 
 (c) Continuous monitoring of water uptake[18]: 
Although previous method has advantage ofun-
disturbance of swollen tablet, but for measuring water 
uptake one has to remove whole assembly outof 
beaker, so process in not continuous. 
Continuous monitoring of water uptake is possible by 
following apparatus. 
In this apparatus, swelling tablet is placed on a glass 
filter as support in one hollow cylinder with smooth 
surface inside, and one light weight punch is placed on 
it to prevent floating. This cylinder is placed pre-heated 
in dissolution medium. Another beaker containing 
dissolution medium reservoir is placed on digital 
balance and both are connected with media filled U 
tube and medium level is kept equal. As tablet swells, 
it absorbs water and water level in outer part of 
cylinder goes down.The decrease in water level is 
maintained by importing extra medium via U tube from 
reservoir beaker.As medium is transfered from 
reservoir, amount of water transfer can be determined 
by observing lossof weight by digital balance. 
B) In vitro dissolution tests[19] 
A. In vitro dissolution test is generally done by using 
USP apparatus with paddle and GRDDS isplaced 
normally as for other conventional tablets. But 
sometimes as the vessel is large and paddles are 
atbottom, there is much lesser paddle force acts on 
floating dosage form which generally floats on surface. 
Asfloating dosage form not rotates may not give proper 
result and also not reproducible results. Similar 
problem occurs with swellable dosage form, as they are 
hydrogel may stick to surface of vessel or paddle and 
gives irreproducible results. 
In order to prevent such problems, various types of 
modifications in dissolution assembly made are as 
follows. 
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B. To prevent sticking at vessel or paddle and to 
improve movement of dosage form, method suggested 
is to keep paddle at surface and not too deep inside 
dissolution medium. 
C. Floating unit can be made fully submerged, by 
attaching some small, loose, non-reacting material,such 
as few turns of wire helix, around dosage form. 
However this method can inhibit three dimensional 
swelling of some dosage form and also affects drug 
release. 
D. Other modification is to make floating unit fully 
submerged under ring or mesh assembly andpaddle is 
just over ring that gives better force for movement of 
unit. 
E. Other method suggests placing dosage form 
between 2 ring/meshes. 
F. In previous methods unit have very small area, 
which can inhibit 3D swelling of swellable 
units,another method suggests the change in dissolution 
vessel that is indented at some above place from 
bottomand mesh is placed on indented protrusions, this 
gives more area for dosage form. 
G. Inspite of the various modifications done to get the 
reproducible results, none of them showed correlation 
with the in vivo conditions. So a novel dissolution test 
apparatus with modification of Rossett-Ricetest 
Apparatus was proposed. 
Rossett-Rice test is used for predicting in-vitro 
evaluation of directly acting antacid (action bychemical 
neutralization of acid), where HClis added gradually to 
mimic the secretion rate of acid from the stomach. 
In this modified apparatus, it has side arm from bottom 
of beaker such that it maintains volume of 70 mL in 
beaker and fresh SGF is added from burette at 2 
mL/min rate. Thus sinkcondition is maintained. 
Stirring is done by magnetic stirrer at 70-75 RPM. 
 
Fig 13: In vitro dissolution tests 
 
(C) In vivo evaluation 
(a) Radiology: X-ray is widely used for examination of 
internal body systems. Barium Sulphate iswidely used 
Radio Opaque Marker. So, BaSO4 is incorporated 
inside dosage form and X-ray images aretaken at 
various intervals to view GR. 
(b) ⊥ -Scintigraphy: Similar to X-ray, ⊥ -emitting 
materials are incorporated into dosage form and then 
images are taken by scintigraphy. Widely used ⊥ -
emitting material is 99Tc. 
(c) Gastroscopy: Gastroscopy is peroral endoscopy 
used with fiber optics or video systems. Gastroscopy is 
used to inspect visually the effect of prolongation in 
stomach. It can also give the detailedevaluation of 
GRDDS. 
(d) Magnetic marker monitoring: In this technique, 
dosage form is magnetically marked with incorporating 
iron powder inside, and images can be taken by very 
sensitive bio-magnetic measurementequipment. 
Advantage of this method is that it is radiation less and 
so not hazardous. 
(e) 
13
C Octanoic acid breath test:
13
C Octanoic acid is 
incorporated into GRDDS. In stomach due to chemical 
reaction, octanoic acid liberates CO2 gas which comes 
out in breath. The important Carbon atom which will 
come out in CO2 is replaced with 
13
C isotope. So time 
upto which 
13
CO2 gas is observed in breath can be 
considered as gastric retention time of dosage form. As 
the dosage form moves to intestine, there is no reaction 
and no CO2 release. So this method is cheaper than 
other.[20] 
 
 
1.5 Different gastroretentive approaches and probable polymers used in them 
 
 
Asian Pac. J. Health Sci., 2016; 3 (4):131-144                                        e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ___________________________________________________________________________________________________________________________________________ 
Fatema et al             ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(4): 131-144 
www.apjhs.com      143 
 
Different gastroretentive approaches Probable polymers  
1)high density (sinking) drug delivery system  Iron powder, barium sulfate, zinc oxide and titanium oxide. 
2)bioadhesive drug delivery system 
 
Anionic polymers: carboxy methylcellulose, poly acrylic acid, chitosan, 
alginic acid.Cationic polymers: polylysine Neutral polymers: polyethylene 
glycol, dextran.[21] 
3)swelling/ expanding systems 
 
All grades of hpmc, polyethylene oxide, hydroxypropyl cellulose, 
hydroxypropyl methyl cellulose, hydroxyethyl cellulose, sodium 
carboxymethyl cellulose, calcium carboxymethyl cellulose, methyl 
cellulose, polyacrylic acid, xanthan gum, and polyvinyl alcohol. 
4)effervescent systems Sodium bicarbonate, citric acid andtartaric acid. 
5)non effervescent systems High levels (20–75% w/w) of one or more gel-forming highly swellable 
cellulosic hydrocolloids. 
 
Conclusion 
 
Above literature concludes that GRDDS is one of the 
efficient technique to maintain the sustained release of 
drug in gastric environment and there by increases its 
absorption and bioavailability. All these GRDDS 
approaches are convenient and more feasible when 
compared to other drug delivery systems and have their 
own advantages and disadvantages. Now a lot of 
research program is going on to develop new 
formulation using different polymers or copolymers 
which are discussed in various patents of this review. 
GRDDS have systemic, localized as well as site 
specific action. GRDDS helps in the treatment of 
various gastrointestinal diseases, and also reduces dose 
frequency thereby minimizing contra indication, 
systemic toxicity, drug dependence. Ultimately 
GRDDS is a simple yet effective drug delivery system. 
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